386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Philippe Aftimos, Nicholas C. Turner, Joyce O’Shaughnessy, Evelyn van den Tweel, M. Oesterholt, Santiago Escrivá-de-Romaní, N. Quenel Tueux, Tira J. Tan, Joline S.J. Lim, Sylvain Ladoire, A.C. Armstronh, Agostina Stradella, Giulia Bianchi, Marco Colleoni, Emilie Kaczmarek, Kevin Punie, X. Song, N.P. Koper, C. Saura Manich